Comparison Between Oral Methotrexate and Tofacitinib in the Treatment Of Chronic Plaque Psoriasis
Journal of Health, Wellness and Community Research · 18.06.2025 · 1-9
DOI: 10.61919/7wng7r53 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Health, Wellness and Community Research, online erschienen am 18.06.2025. Verfasst von Maryam Fatima und 3 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Chronic plaque psoriasis is a systemic immune-mediated inflammatory disease requiring effective systemic therapy in patients with moderate-to-severe disease or inadequate response to topical treatment. Methotrexate remains widely used because of affordability and availability, while tofacitinib offers targeted oral Janus kinase inhibition with potential efficacy in plaque psoriasis.
Objective
To compare the efficacy and short-term safety of oral tofacitinib and oral methotrexate in patients with chronic plaque psoriasis.
Methods
This randomized controlled trial was conducted at the Department of Dermatology, Lahore General Hospital, Lahore, from February 2025 to June 2025. Seventy-five patients aged 18–70 years with chronic plaque psoriasis of at least 6 months’ duration, PASI score ≥10 or body surface area involvement ≥10%, and inadequate response to topical therapy were included. Group A received oral tofacitinib 5 mg twice daily, while Group B received oral methotrexate once weekly, starting at 10 mg and titrated according to response and tolerance. Patients were followed for 12 weeks. The primary outcome was PASI-75 achievement at week 12.
Results
Tofacitinib was given to 38 patients and methotrexate to 37 patients. Mean PASI decreased from 18.6 ± 4.4 to 4.9 ± 3.1 with tofacitinib and from 18.2 ± 4.6 to 6.7 ± 3.7 with methotrexate. Mean percentage PASI reduction was higher with tofacitinib than methotrexate. PASI-75 was achieved by 23 patients (60.5%) receiving tofacitinib and 16 patients (43.2%) receiving methotrexate. Any adverse event occurred in 10 patients (26.3%) in the tofacitinib group and 12 patients (32.4%) in the methotrexate group.
Conclusion
Both oral tofacitinib and methotrexate improved PASI score over 12 weeks. Tofacitinib produced greater mean PASI reduction and numerically higher PASI-75 response, although categorical response superiority was not statistically confirmed. Both drugs were generally tolerated during short-term follow-up.
Zitieren
APA
Fatima, M., Shehzad, A., Kamal, T., & Khan, M. U. (2025). Comparison Between Oral Methotrexate and Tofacitinib in the Treatment Of Chronic Plaque Psoriasis. Journal of Health, Wellness and Community Research, 1-9. https://doi.org/10.61919/7wng7r53
Vancouver
Fatima M, Shehzad A, Kamal T, Khan MU. Comparison Between Oral Methotrexate and Tofacitinib in the Treatment Of Chronic Plaque Psoriasis. Journal of Health, Wellness and Community Research. 2025:1-9. doi:10.61919/7wng7r53
BibTeX
@article{Fatima2025,
author = {Fatima, Maryam and Shehzad, Atif and Kamal, Tahir and Khan, Muhammad Umair},
title = {Comparison Between Oral Methotrexate and Tofacitinib in the Treatment Of Chronic Plaque Psoriasis},
journal = {Journal of Health, Wellness and Community Research},
year = {2025},
pages = {1--9},
doi = {10.61919/7wng7r53}
}
EUVIMED